Titan Pharmaceuticals, Inc. Income (Loss) from Continuing Operations, Per Basic Share
Titan Pharmaceuticals, Inc. reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.18 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2022-08-11
- Titan Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2022-06-30 was -$0.18.
- Titan Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2022-03-31 was -$0.24.
- Titan Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2021-06-30 was -$0.17.
- Titan Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2021-03-31 was -$0.28.
- Titan Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for fiscal 2021 was -$0.90.
- Titan Pharmaceuticals, Inc. income (loss) from continuing operations, per basic share for fiscal 2020 was -$1.96.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|
| 2022-06-30 | -$0.18 10-Q · filed 2022-08-11 | -$0.41 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$0.24 10-Q · filed 2022-05-16 | ||
| 2021-12-31 | -$0.90 10-K · filed 2022-03-25 | ||
| 2021-06-30 | -$0.17 10-Q · filed 2022-08-11 | -$0.45 10-Q · filed 2022-08-11 | |
| 2021-03-31 | -$0.28 10-Q · filed 2022-05-16 | ||
| 2020-12-31 | -$1.96 10-K · filed 2022-03-25 |